Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InhaleRx Limited ( (AU:IRX) ) just unveiled an announcement.
InhaleRx Limited has issued a proxy voting form and instructions for shareholders ahead of its general meeting scheduled for 4:00pm (AEDT) on Thursday, 29 January 2026, to be held virtually. The materials outline how shareholders can appoint proxies, submit voting instructions through various channels, and direct votes on a series of resolutions, including ratification of prior share issues, approvals for multiple tranches of placement securities and options (including to the lead manager and under a facility agreement), and a proposal to change the company’s name to Nexalis Therapeutics Limited. The documentation clarifies procedural rules for proxy appointments, default voting by the chair, and corporate representation, underscoring a significant capital-structure and branding agenda that, if approved, would formalise recent financing activities and rebrand the company, potentially signalling a strategic repositioning for investors and other stakeholders.
More about InhaleRx Limited
InhaleRx Limited is an Australian-listed company, but this document does not provide detail on its specific industry, core products, or services. The release instead focuses on governance and shareholder procedures around an upcoming general meeting.
Average Trading Volume: 287,952
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.39M
Find detailed analytics on IRX stock on TipRanks’ Stock Analysis page.